

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (Currently amended) A method for ~~modulating~~decreasing levels of vWF or FVIII in an animal, the method comprising  
administering to the animal an effective dose of an inhibitor of ST3Gal-IV sialyltransferase enzyme activity, wherein said inhibitor is an analog of a ST3Gal-IV substrate and said animal is suffering from atherosclerosis or a blood clotting disorder, and whereby levels of vWF or FVIII in the animal are decreased.

2-5. (Canceled)

6. (Previously presented) The method of claim 1, wherein the method is performed in conjunction with administration of a drug for which blood clotting is a potential side effect.

7. (Previously presented) The method of claim 6, wherein the ST3Gal-IV sialyltransferase inhibitor is administered before or simultaneously with the drug for which blood clotting is a potential side effect.

8-9. (Canceled)

10. (Previously presented) The method of claim 1, wherein the method is performed as a therapeutic measure against atherosclerosis.

11. (Original) The method of claim 10, wherein the atherosclerosis is associated with coronary artery disease or peripheral arterial disease.

12. (Previously presented) The method of claim 1, wherein platelet formation is not significantly affected by administration of the ST3Gal-IV sialyltransferase inhibitor to the animal

13-28. (Canceled)

29. (Previously presented) The method of claim 1, further comprising monitoring the animal for levels of vWF or FVIII.

30. (Previously presented) The method of claim 29, further comprising adjusting the dose of the ST3Gal-IV sialyltransferase inhibitor to maintain vWF at a desired level.

31-36. (Canceled)

37. (Previously presented) The method of claim 6, wherein the drug for which blood clotting is a potential side effect is selected from the group consisting of an anti-cancer drug, a corticosteroid, raloxifene, and a birth control agent.

38. (Previously presented) The method of claim 37, wherein the anti-cancer drug is tamoxifen.

39. (Previously presented) The method of claim 37, wherein the birth control agent is an estrogen or a progestin.

40. (Previously presented) A method for modulating levels of vWF or FVIII in an animal, the method comprising

administering to the animal an effective dose of an inhibitor of ST3Gal-IV sialyltransferase enzyme activity, wherein said inhibitor is an analog of a ST3Gal-IV substrate and whereby levels of vWF or FVIII in the animal are decreased; and

monitoring the animal for levels of vWF or FVIII.